Delving into the Latest Updates on V023-9340 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms-

Target

FXR

Mechanism

FXR antagonists(Bile acid receptor FXR antagonists)

Therapeutic Areas

Digestive System Disorders

Active Indication

Metabolic dysfunction-associated steatotic liver disease

Inactive Indication-

Originator Organization

Guilin Medical College

Active Organization

Guilin Medical College

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Farnesoid X receptor (FXR) plays a key role in bile acid homeostasis, inflammation, fibrosis, lipid and glucose metabolism and is emerging as a promising therapeutic target for nonalcoholic steatohepatitis (NASH). Emerging evidence suggested that intestine-specific FXR antagonists exhibited remarkable metabolic improvements and slowed NASH progression. In this study, we discovered several potent FXR antagonists using a multistage ligand- and structure-based virtual screening approach. Notably, compound V023-9340, which possesses a 4-aminophenylacetamide scaffold, emerged as the most potent FXR antagonist with an IC₅₀ value of 4.27 μM. In vivo, V023-9340 demonstrated selective accumulation in the intestine, substantially ameliorating high-fat diet (HFD)-induced NASH in mice by mitigating hepatic steatosis and inflammation. Mechanistic studies revealed that V023-9340 strongly inhibited intestinal FXR while concurrently feedback-activated hepatic FXR. Further structure-activity relationship optimization employing V023-9340 has resulted in the synthesis of a more efficacious compound V02-8 with an IC₅₀ value of 0.89 μM, which exhibited a 4.8-fold increase in FXR antagonistic activity compared to V023-9340. In summary, 4-aminophenylacetamide derivative V023-9340 represented a novel intestine-specific FXR antagonist and showed improved effects against HFD-induced NASH in mice, which may serve as a promising lead in discovering potential therapeutic drugs for NASH treatment.

100 Deals associated with V023-9340

Login to view more data